

GILEAD SCIENCES INC  
Form 8-K  
April 20, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 19, 2006**

---

**GILEAD SCIENCES, INC.**

(Exact Name of Registrant as Specified in Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**0-19731**  
(Commission File Number)

**94-3047598**  
(IRS Employer  
Identification No.)

**333 Lakeside Drive, Foster City, California**  
(Address of Principal Executive Offices)

**94404**  
(Zip Code)

**Registrant's telephone number, including area code: (650) 574-3000**

**N/A**

(Former name or former address, if changed since last report.)

---

## Edgar Filing: GILEAD SCIENCES INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**Item 8.01 Other Events**

On April 20, 2006, Gilead Sciences, Inc. announced the pricing, on April 19, 2006, of its private offering of \$600 million principal amount of 0.50% Convertible Senior Notes due 2011 and \$600 million principal amount of 0.625% Convertible Senior Notes due 2013. A copy of the press release is attached hereto as Exhibit 99.1, is incorporated herein by reference, and is hereby filed.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press release, dated April 20, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: April 19, 2006

GILEAD SCIENCES, INC.

/s/ JOHN F. MILLIGAN

John F. Milligan

Executive Vice President and Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Document Description</b>
99.1	Press release, dated April 20, 2006